EZZ Life Science Holdings Limited (ASX:EZZ)
Australia · Delayed Price · Currency is AUD 1.765
-0.070 (-3.81%)
Jan 30, 2026, 2:18 PM AEST
EZZ Life Science Holdings Revenue
In the fiscal year ending June 30, 2025, EZZ Life Science Holdings had annual revenue of 66.87M AUD with 0.65% growth. EZZ Life Science Holdings had revenue of 36.59M in the half year ending June 30, 2025, with 66.17% growth.
Revenue
66.87M
Revenue Growth
+0.65%
P/S Ratio
1.29
Revenue / Employee
n/a
Employees
n/a
Market Cap
86.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 66.87M | 430.32K | 0.65% |
| Jun 30, 2024 | 66.44M | 29.30M | 78.88% |
| Jun 30, 2023 | 37.14M | 22.12M | 147.26% |
| Jun 30, 2022 | 15.02M | -7.27M | -32.60% |
| Jun 30, 2021 | 22.29M | 4.32M | 24.03% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 12.51M |
| Alterity Therapeutics | 5.44M |
| Amplia Therapeutics | 5.01M |
| Imugene | 4.40M |
| Prescient Therapeutics | 4.36M |
| Arovella Therapeutics | 3.44M |
| Proteomics International Laboratories | 3.31M |
| Cynata Therapeutics | 1.89M |